Mycophenolate revisited

@article{Gelder2015MycophenolateR,
  title={Mycophenolate revisited},
  author={T. Gelder and D. Hesselink},
  journal={Transplant International},
  year={2015},
  volume={28}
}
The patent of mycophenolate mofetil (MMF) has expired, and for enteric‐coated mycophenolate sodium (EC‐MPS), this will happen in 2017. In the twenty years these drugs have been used, they have become extremely popular. In this review, the reasons for the popularity of mycophenolate are discussed, including the benefits compared to azathioprine. MMF and EC‐MPS are therapeutically equivalent. Although neither is considered to be a narrow therapeutic index drug, this should not lead to careless… Expand
The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy
TLDR
It would appear that MMF therapy should be subject to TDM to avoid over- and under-dosing, and this may be a viable strategy to reduce treatment-emergent adverse events and to increase the effective pediatric transplant survival rates. Expand
In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy
TLDR
The data indicate that if immunosuppressant therapy is indispensable, efficacy of CIK cells is maintained at least short-term, although more frequent dosing might be necessary. Expand
Generic immunosuppressants
TLDR
The institution of ‘innovator only’ policies may be appropriate at this time in order to minimize the risk of under-immunosuppressing patients until the evidence of more stringent bioequivalence has been established. Expand
Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.
  • F. Macaluso, M. Maida, +8 authors A. Orlando
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2017
TLDR
This is the first experience reporting a clinical benefit and tolerability of mycophenolate mofetil in patients with inflammatory bowel disease and multiple previous failures to other immunosuppressants and/or biologics. Expand
Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil
TLDR
Physicians in the field of transplantation should be aware of the potential risk of altering the therapeutic outcome when switching from one preparation of MMF to another, and bioequivalence between these generics may be difficult to show. Expand
The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients
TLDR
It is unlikely that the lower incidence of acute rejection in elderly patients, or the higher risk to die from a severe infection in elderly Patients is due to different handling of MPA in the elderly, because of differences in the immunosuppressive drugs they are taking. Expand
Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention
TLDR
There remains a need for consensus on practical aspects of mycophenolate target concentration intervention in contemporary tacrolimus-containing regimens and future research to define maintenance phase exposure targets, but given ongoing consequences of both overimmunosuppression and underimmunOSuppression in kidney transplantation, these should be a priority. Expand
Mycophenolic acid pharmacogenomics in kidney transplantation
TLDR
A review of M PA pharmacogenomic studies, included pharmacokinetics, adverse events, and main clinical outcomes of MPA treatment in kidney transplantation, and associations of variants in genes encoding MPA metabolizing enzymes, transporters, and targets with drug efficacy and safety are described. Expand
Usage of Tacrolimus and Mycophenolic Acid During Conception, Pregnancy, and Lactation, and its Implications for Therapeutic Drug Monitoring: A Systematic Critical Review.
TLDR
Tac treatment during conception, pregnancy, and lactation seems to be safe in terms of the health of the mother, (unborn) child, and allograft, however, Tac may increase the risk of hypertension, preeclampsia, preterm birth, and low birth weight. Expand
The effect of mycophenolate mofetil on platelet function.
TLDR
MMF and MPA only had a minor effect on collagen-induced platelet aggregation, with MPA reducing the relative disposition of surface collagen-receptor GPVI receptors. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Enteric‐Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novo Renal Transplant Patients
  • M. Salvadori, H. Holzer, +5 authors M. Hall
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2004
TLDR
Therapeutic equivalence of EC‐MPS and MMF (1000 mg MMF b.i.d.), with concomitant cyclosporine microemulsion (Neoral®) and corticosteroids, was assessed in 423 de novo kidney transplant patients recruited to a 12‐month, double‐blind study. Expand
Therapeutic Drug Monitoring for Mycophenolic Acid Is Value for (Little) Money
TLDR
It is remarkable to see that there is still debate over whether to carry out TDM for mycophenolic acid, and, particularly in patients at high risk of acute rejection, TDM could lead to benefit. Expand
Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies
TLDR
There is strong evidence that maintenance CIN-MMFsteroid-based triple therapy, initiated in the early posttransplant period significantly reduces the risk of acute rejection in the first post-transplant year, when compared to double therapy regimens comprising CIN and steroids alone. Expand
The role of mycophenolate mofetil in kidney transplantation revisited.
TLDR
This review will revisit the question of whether the available evidence continues to support the superiority of MMF over AZA in kidney transplantation outcomes while comprehensively reviewing the availableevidence from clinical trial data, systematic reviews, and registry studies. Expand
PHARMACOKINETICS OF MYCOPHENOLATE SODIUM AND COMPARISON WITH THE MOFETIL FORMULATION IN KIDNEY TRANSPLANT RECIPIENTS.
TLDR
Given the emerging clinical benefit of mycophenolic acid monitoring in the transplant setting, therapeutic drug monitoring problems with the enteric-coated formulation of myCophenolate sodium should be taken into account. Expand
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
TLDR
MPA exposure should be measured and doses should be adjusted accordingly to achieve optimal clinical outcomes and limited sampling strategies to estimate MPA exposure from EC-MPS have not yet been well developed and fully evaluated, nor have accurate Bayesian estimators been reported. Expand
Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation
  • Y. Le Meur, M. Büchler, +13 authors P. Marquet
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
TLDR
Therapeutic MPA monitoring using a limited sampling strategy can reduce the risk of treatment failure and acute rejection in renal allograft recipients 12 months posttransplant with no increase in adverse events. Expand
Limits to Intensified Mycophenolate Mofetil Dosing in Kidney Transplantation
TLDR
If intensified MPA dosing is considered, exceeding 3 g daily in tacrolimus-treated patients provides no added benefit and 4 g daily dose does not result in a greater proportion of patients achieving adequate MPA exposure. Expand
Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
  • D. Capone, G. Tarantino, +4 authors M. Sabbatini
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2011
TLDR
Limited sampling strategies are useful for MPA AUC(0-12) estimation in patients receiving EC-MPS and cyclosporine, and an optimal agreement between the full and estimated AUCs is shown by using the validation group of patients. Expand
Pharmacokinetic and Pharmacodynamic Comparison of Enteric‐Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients
  • K. Budde, S. Bauer, +6 authors P. Glander
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
TLDR
Overall, IMPDH activity reflected MPA pharmacokinetics, and equimolar doses of EC‐MPS and MMF produce equivalent MPA exposure, while the delayed release formulation of EC-MPS exhibits more variable predose levels and Tmax. Expand
...
1
2
3
4
5
...